In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.

Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.

As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...

Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.

After today, andexanet alfa (Andexxa; AstraZeneca) will no longer be made or sold in the United States, according to an alert from the US Food and Drug Administration.

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...

Angina patients with no obstructive CAD had no worse outcomes over 15 years, perhaps because they got the care they needed.

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.